Highlight
- Lisocabtagene maraleucel (liso-cel) yields a median overall survival of 27.5 months in relapsed or refractory large B-cell lymphoma (R/R LBCL) patients.
- Estimated five-year overall survival (OS) reaches 38% in efficacy-evaluable patients, supporting durable responses.
- Disease-specific survival (DSS) estimates at five years show even higher rates, suggesting sustained control of lymphoma-related mortality.
- Long-term follow-up reveals no new safety concerns, with low rates of late severe infections and second primary malignancies, underscoring a favorable safety profile.
Specialty calculators
For clinical reference; use professional judgment.
